Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment
Cells · 03.11.2026 · 15 (21) · 2004
DOI: 10.3390/cells15212004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 03.11.2026. Verfasst von Patrick J Stiff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Building 112, 2160 South First Avenu…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Ovarian Neoplasms. Die Arbeit nennt 273 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ovarian cancer is a lethal gynecologic malignancy with limited effective treatment options. It is expected that in 2026 there will be about 21,010 new cases of ovarian cancer diagnosed and about 12,450 deaths within the United States. Unfortunately, conventional therapies such as chemotherapy and radiation have limited efficacy for high-grade serous ovarian cancer (HGSOC) and also produce significant toxicity. HGSOC is characterized by an ovarian tumor microenvironment (TME) consisting of immune inhibitory T regulatory cells and inhibitory tumor-associated macrophages, including myeloid-derived suppressor cells (MDSCs) and M2 cells, which confer immune suppression. Immunocompetent T cells, tumor-suppressing M1 cells, natural killer cells, and other cellular subsets are also present. The TME is further shaped by soluble molecules, extracellular matrix, and other structural components, as well as the presence of blood vessels and ascitic fluid in the peritoneal cavity, which aid in the distribution of cancer cells to the omentum where more lesions soon develop. This review outlines the heterogenous immune cell subsets in the ovarian TME and other structural targets that promote or reduce cancer burden. Most single-agent immune strategies have shown limited efficacy in unselected HGSOC populations due to the complex immune-suppressive nature of the TME. Here, we also discuss novel combination treatments in clinical trials or in clinical practice for HGSOC. Advances in understanding the ovarian TME will reveal new immunotherapy and drug targets for translational medicine and aid in determining effective drug and immunotherapy combinations, which may ultimately lead to improved overall survival in HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA.
- Division of Hematology, Oncology and Palliative Care, UW School of Medicine and Public Health, University of Wisconsin (UW) Carbone Cancer Center, 600 N. Highland Avenue, K4/530, Madison, WI 53792, USA.
- Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.
- Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.
ORCID-Profile: Cheryl M Czerlanis, William Small
Zitieren
APA
Stiff, P. J., Czerlanis, C. M., Potkul, R. K., Small, W., & Drakes, M. L. (2026). Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment. Cells, 15(21), 2004. https://doi.org/10.3390/cells15212004
Vancouver
Stiff PJ, Czerlanis CM, Potkul RK, Small W, Drakes ML. Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment. Cells. 2026;15(21):2004. doi:10.3390/cells15212004
BibTeX
@article{Stiff2026,
author = {Stiff, Patrick J and Czerlanis, Cheryl M and Potkul, Ronald K and Small, William and Drakes, Maureen L},
title = {Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment},
journal = {Cells},
year = {2026},
volume = {15},
number = {21},
pages = {2004},
doi = {10.3390/cells15212004}
}
EUVIMED